Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Institute of Urology, Anhui Medical University, Hefei, China.
FASEB J. 2020 Oct;34(10):14006-14023. doi: 10.1096/fj.201902910RRR. Epub 2020 Aug 30.
Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) is a complicated syndrome characterized by genitourinary pain in the absence of bacterial infection. Th17 cell-driven autoimmunity has been proposed as a cause of CP/CPPS. However, the factors that promote Th17-driven autoimmunity in experimental autoimmune prostatitis (EAP) and the molecular mechanisms are still largely unknown. Here, we showed that Th17 cells were excessively activated, and blockade of IL-17A could effectively ameliorate various symptoms in EAP. Furthermore, we revealed that calcium/calmodulin-dependent kinase Ⅳ (CaMK4), especially Thr p-CaMK4 was increased in the Th17 cells of the EAP group, which were activated by intracellular cytosolic Ca . Pharmacologic and genetic inhibition of CaMK4 decreased the proportion of Th17 cells, and the protein and mRNA level of IL-17A, IL-22, and RORγt. The phosphorylation of CaMK4 was dependent on the increase in intracellular cytosolic Ca concentration in Th17 cells. A mechanistic study demonstrated that inhibition of CaMK4 reduced IL-17A production by decreasing the phosphorylation of Akt-mTOR, which was well accepted to positively regulate Th17 differentiation. Collectively, our results demonstrated that Ca -CaMK4-Akt/mTOR-IL-17A axis inhibition may serve as a promising therapeutic strategy for CP/CPPS.
慢性前列腺炎和慢性骨盆疼痛综合征(CP/CPPS)是一种以泌尿生殖系统疼痛为特征的复杂综合征,而无细菌感染。Th17 细胞驱动的自身免疫被认为是 CP/CPPS 的一个原因。然而,实验性自身免疫性前列腺炎(EAP)中促进 Th17 驱动自身免疫的因素及其分子机制在很大程度上仍然未知。在这里,我们表明 Th17 细胞过度激活,阻断 IL-17A 可有效改善 EAP 的各种症状。此外,我们揭示了钙/钙调蛋白依赖性激酶 4(CaMK4),特别是 Thrp-CaMK4 在 EAP 组的 Th17 细胞中增加,被细胞内细胞质 Ca 激活。CaMK4 的药理学和遗传学抑制降低了 Th17 细胞的比例,以及 IL-17A、IL-22 和 RORγt 的蛋白和 mRNA 水平。CaMK4 的磷酸化依赖于 Th17 细胞内细胞质 Ca 浓度的增加。一项机制研究表明,CaMK4 的抑制通过降低 Akt-mTOR 的磷酸化来减少 IL-17A 的产生,这被广泛认为可以正向调节 Th17 分化。总之,我们的研究结果表明,Ca-CaMK4-Akt/mTOR-IL-17A 轴的抑制可能是 CP/CPPS 的一种有前途的治疗策略。